Foundry Partners LLC Purchases 81,337 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Foundry Partners LLC boosted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 1,597.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 86,429 shares of the specialty pharmaceutical company's stock after purchasing an additional 81,337 shares during the period. Foundry Partners LLC owned approximately 0.14% of Jazz Pharmaceuticals worth $10,730,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Quadrant Capital Group LLC raised its stake in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after acquiring an additional 101 shares in the last quarter. Elequin Capital LP increased its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $28,000. Allianz SE purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at approximately $29,000. Finally, Parallel Advisors LLC increased its holdings in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total value of $107,630.00. Following the completion of the sale, the chief executive officer owned 436,973 shares in the company, valued at $47,031,403.99. This trade represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Seamus Mulligan bought 1,621 shares of the business's stock in a transaction on Monday, May 12th. The shares were acquired at an average price of $103.00 per share, with a total value of $166,963.00. Following the transaction, the director owned 101,621 shares of the company's stock, valued at $10,466,963. The trade was a 1.62% increase in their position. The disclosure for this purchase can be found here. Insiders have sold 2,500 shares of company stock valued at $277,930 in the last quarter. Insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

JAZZ has been the topic of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Royal Bank Of Canada cut their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Morgan Stanley lowered their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. Finally, Piper Sandler reiterated an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $181.71.

Jazz Pharmaceuticals Trading Down 1.7%

Shares of NASDAQ:JAZZ opened at $112.87 on Friday. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company's 50 day moving average is $109.13 and its two-hundred day moving average is $118.28. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The company has a market cap of $6.83 billion, a PE ratio of 15.05, a P/E/G ratio of 5.74 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The company had revenue of $897.84 million during the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The company's quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the business earned $2.68 earnings per share. Equities analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.